Lemtrada Lasting Benefits
Two Phase 3 clinical trials investigating the long-term effects of Lemtrada (alemtuzumab) in multiple sclerosis (MS) patients showed the drug maintained improved outcomes, even in the absence of further treatment.

In these patients, part of the CARE-MS II study (NCT00548405), Lemtrada (12 mg) treatment demonstrated significantly greater improvements on clinical and MRI outcomes when compared to Rebif (interferon beta-1a), another drug approved as an MS therapy.

Also, Lemtrada-treated patients who were followed an additional four years in an extension study (NCT00930553) showed durable effectiveness on clinical and MRI outcomes in the absence of continuous treatment. In fact, the majority of the patients received no additional therapy neither Lemtrada nor any other disease-modifying therapies.